Methods for Assessing the Quality of Biomedical Cell Products for Skin Replacement
The aim of the study was the development of methods to assess the quality of biomedical cell products (BMCPs) intended to replace skin defects.
Materials and Methods. The proposed equivalent of the skin BMCP-1 (developed at the N.K. Koltsov Institute of Developmental Biology, Russian Academy of Sciences) and the BMCP-2 equivalent of the skin (developed at the Privolzhsky Research Medical University) were studied. Mesenchymal stem cells (MSCs) from human adipose tissue served as the cellular components of both BMCPs.
MSCs in suspensions and in BMCPs were tested for cell counts and cell viability. The BMCPs were studied in their entirety without destruction using fluorescence microscopy with vital dyes for staining the cytoplasm and Hoechst 3334 (BD Pharmingen, USA) — for nuclei (imager Cytation 5; BioTek, USA).
The MSC function was evaluated by their ability to produce VEGF-A. The MSC phenotype was determined by cytometry.
Results. Using the above methods, we found that MSCs in BMCP retained their original morphology and viability. On the surface of BMCP-1, cells are organized in colonies, whereas in the structure of BMCP-2, they are scattered throughout the matrix. The number of cells in BMCP-1 depends on the transportation conditions; and in the structure of BMCP-2 — on the timing of cultivation. The secretory activity of MSCs is maintained throughout the entire observation period.
While within the BMPC structures, the MSCs had their CD90 expression decreased; it was then restored after the cells were isolated from the products and cultivated on the plastic surface.
Conclusion. The proposed method is feasible for the BMCP quality assessment; it incorporates the requirements for production and transportation based on the characteristics of the cellular and non-cellular components. Given the optical non-transparency and complex physical-chemical structure of the product, it is advisable to select the quality control methods that ensure minimal manipulation and enzymatic damage.
- Pyatigorskaya N.V., Tulina M.A., Aladysheva Zh.I., Beregovykh V.V. International approaches to the regulation of cell therapy products. Vestnik Rossiiskoi akademii meditsinskikh nauk 2013; 68(8): 4–8.
- Federal’nyy zakon RF ot 23 iyunya 2016 g. No.180-FZ “O biomeditsinskikh kletochnykh produktakh” [Federal Law of the Russian Federation dated June 23, 2016 No.180-FZ “About biomedical cell products”].
- Prikaz Ministerstva zdravookhraneniya Rossiyskoy Federatsii ot 08.08.2018 g. No.512n “Ob utverzhdenii Pravil nadlezhashchey praktiki po rabote s biomeditsinskimi kletochnymi produktami” [Order of the Ministry of Health of the Russian Federation dated 08.08.2018, No.512n “On the approval of the Rules of good practice for working with biomedical cellular products”].
- Metodicheskie rekomendatsii po provedeniyu doklinicheskikh issledovaniy biomeditsinskikh kletochnykh produktov [Guidelines for preclinical studies of biomedical cell products]. Pod red. Tkachuka V.A. [Tkachuk V.A. (editor)]. Moscow: MGU im. M.V. Lomonosova; 2017; 302 p.
- Egorikhina M.N., Levin G.Ya., Charykova I.N., Aleynik D.Ya., Sosnina L.N. Method for creating a bioresorbable cellular scaffold based on fibrin of blood plasma. Patent RU 2653434. 2018.
- Granero-Molto F., Weis J.A., Longobardi L., Spagnoli A. Role of mesenchymal stem cells in regenerative medicine: application to bone and cartilage repair. Expert Opin Biol Ther 2008; 8(3): 255–268, https://doi.org/10.1517/14712598.8.3.255.
- Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D.J., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4): 315–317, https://doi.org/10.1080/14653240600855905.
- Egorikhina M.N., Charykova I.N., Aleynik D.Ya. Method of quantitative analysis of cellular components of scaffold. Patent RU 2675376. 2018.
- Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18(1): 4–25, https://doi.org/10.1210/edrv.18.1.0287.
- Nakagami H., Maeda K., Morishita R., Iguchi S., Nishikawa T., Takami Y., Kikuchi Y., Saito Y., Tamai K., Ogihara T., Kaneda Y. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vasc Biol 2005; 25(12): 2542–2547, https://doi.org/10.1161/01.atv.0000190701.92007.6d.
- Rehman J., Traktuev D., Li J., Merfeld-Clauss S., Temm-Grove C.J., Bovenkerk J.E., Pell C.L., Johnstone B.H., Considine R.V., March K.L. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004; 109(10): 1292–1298, https://doi.org/10.1161/01.cir.0000121425.42966.f1.
- Nasser M., Wu Y., Danaoui Y., Ghosh G. Engineering microenvironments towards harnessing pro-angiogenic potential of mesenchymal stem cells. Mater Sci Eng C Mater Biol Appl 2019; 102: 75–84, https://doi.org/10.1016/j.msec.2019.04.030.
- Reisbig N.A., Hussein H.A., Pinnell E., Bertone A.L. Evaluation of equine synovial-derived extracellular matrix scaffolds seeded with equine synovial-derived mesenchymal stem cells. Am J Vet Res 2018; 79(1): 124–133, https://doi.org/10.2460/ajvr.79.1.124.
- Lee H.C., An S.G., Lee H.W., Park J.S., Cha K.S., Hong T.J., Park J.H., Lee S.Y., Kim S.P., Kim Y.D., Chung S.W., Bae Y.C., Shin Y.B., Kim J.I., Jung J.S. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circ J 2012; 76(7): 1750–1760, https://doi.org/10.1253/circj.cj-11-1135.
- Wu S.C., Pollak R., Frykberg R.G., Zhou W., Karnoub M., Jankovic V., Fischkoff S.A., Chitkara D. Safety and efficacy of intramuscular human placenta-derived mesenchymal stromal-like cells (cenplacel [PDA-002]) in patients who have a diabetic foot ulcer with peripheral arterial disease. Int Wound J 2017; 14(5): 823–829, https://doi.org/10.1111/iwj.12715.
